Abstract: Illustrative embodiments herein disclosed relate to protein arrays, methods for making the arrays and methods for using them, among others. In some embodiments known proteins representing at least 50% of the loci in the human genome are arrayed in known positions on a support. In some embodiments arrays are made of proteins purified from cell lysates by affinity binding to the support. In some embodiments protein arrays are used to decode the binding specificity of antibodies. In some embodiments protein arrays are used to diagnose auto-immune disorders. Many other embodiments and general features are disclosed.

Abstract: The present invention relates to all facets of novel polynucleotides for melanocortin-1 receptors, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions especially relating to melanocortin-1, such as melanoma, pigmentation disorders and conditions, inflammation, etc.

Abstract: The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides, Urb-ctf, are expressed in breast cancer and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions especially related to breast cancer.

Abstract: The present invention relates to genes and genes clusters which are expressed in a tissue specific maner. For example, the invention relates to a group of genes encoding GPCR-like receptors that are involved in the function and activity of the immune system. These genes are organized into a discrete cluster at chromosomal location 1q22 (the “immune gene complex”) and span about 700 kb of DNA. The region closest to the centromere comprises genes that are expressed predominantly in the thymus, while the distal region comprises genes which are expressed predominantly in the bone marrow and other hematopoietic cells. Another cluster of GPCR genes is located at chromosomal band 11q24. These genes are expressed predominantly in pancreatic tissue, establishing this region of chromosome 11 as a unique gene complex involved in pancreatic function. A cluster of transmembrane and GPCR-type receptor genes is also located at chromosomal band 11q12.2.

Abstract: The present invention relates to the histamine H2 receptor (H2R), a member of the G-protein-coupled heptahelical receptor family. This novel H2 receptor codes for a novel carboxy-terminal tail which imparts important regulatory functions to the receptor, e.g., in down-regulation, signal transduction, and in coupling the activity of the H2R to downstream effector molecules, such as G-protein-coupled receptor kinases (GRK). The present invention relates to all facets of this new form of the H2R receptor, including nucleic acids that encode it, H2R polypeptides, binding-partners thereto, as well as its use in research, diagnosis, drug discovery, validation, and targeting, therapy, and clinical medicine.

Abstract: The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine, etc. The polynucleotides are expressed in prostate and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions relating to prostate, such as prostate cancers, as well as other disease and conditions.

Abstract: The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are differentially-regulated in prostate cancer and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, to prostate cancer.

Abstract: The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are expressed in heart and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions of the heart and eye.

Abstract: The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are modulated during angiogeneis and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, determining predisposition to, etc., diseases and conditions, such as abnormal, insufficient, excessive, etc.

Abstract: The present invention relates to all facets of a novel polynucleotide, Tbx3-pr408, the polypeptides it encodes, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, such as mammary-ulnar syndrome and other developmental disorders.

Abstract: The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to diseases and conditions, especially relating to brain and pancreas.

Abstract: The present invention relates to a arrays of nucleic acid and methods of screening these arrays for desired nucleotide sequences. In a preferred embodiment of the invention, a desired cDNA clone can be obtained in three or less rounds of PCR screening. A master plate containing a population of cDNA, distributed in a plurality of wells, is screened for a desired clone by PCR. After a master well containing the desired cDNA is identified, a second plate containing a cDNA array of the master well can then be screened using the same PCR primers. Since the second plate contains about 50-fold to 100-fold fewer clones than the master plate, an expedient reduction in the number of candidates can be achieved in a single PCR step. The invention also relates to a super-master plate containing at least two, preferably more, different populations of cDNA obtainable from different sources of mRNA.

Abstract: The present invention relates to a arrays of nucleic acid and methods of screening these arrays for desired nucleotide sequences. In a preferred embodiment of the invention, a desired cDNA clone can be obtained in three or less rounds of PCR screening. A master plate containing a population of cDNA, distributed in a plurality of wells, is screened for a desired clone by PCR. After a master well containing the desired cDNA is identified, a second plate containing a cDNA array of the master well can then be screened using the same PCR primers. Since the second plate contains about 50-fold to 100-fold fewer clones than the master plate, an expedient reduction in the number of candidates can be achieved in a single PCR step. The invention also relates to a super-master plate containing at least two, preferably more, different populations of cDNA obtainable from different sources of mRNA.